Gasorbol Gotas

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gasorbol Gotas

Property	Description
Active Ingredients	Pipenzolate Bromide and Simethicone
Form	Oral Liquid (Suspension / Drops)
Pharmacological Class	Anticholinergic Agent / Spasmolytic and Antiflatulent
Common Use	Relief of cramps, gas, bloating, and spasms
Origin	Synthetic Components

Identity and Classification of Gasorbol Gotas

Gasorbol Gotas is defined as a specialized combination drug formulated as an oral liquid or suspension (drops), intended for the symptomatic management of simultaneous gastrointestinal muscle spasms and excess gas. This presentation as Gotas is particularly suitable for administration to infants and young children, a common target patient group for relief from infantile colic. The product's high-level pharmacological classification is established by its components: it functions as a combination of an Anticholinergic Agent / Spasmolytic and an Antiflatulent. This dual classification ensures that the medication addresses the two most common root causes of acute gastrointestinal discomfort within a single medication.

Active Ingredients: Pipenzolate Bromide and Simethicone

The active foundation of the medicine consists of two distinct components: Pipenzolate Bromide and Simethicone, both derived from synthetic origins. Pipenzolate Bromide is the agent responsible for the spasmolytic effect, while Simethicone is the physical agent that manages gas accumulation. The components are delivered in an aqueous suspension vehicle, which is necessary to ensure the Simethicone is physically present throughout the digestive tract to perform its gas-dispersing function immediately upon oral administration. Simethicone acts by reducing the surface tension of gas bubbles to aid in their passage.

General Purpose: Relief from Gas and Spasms

The general therapeutic purpose of Gasorbol Gotas is the comprehensive symptomatic relief of painful gastrointestinal disorders characterized by the concurrent appearance of painful intestinal spasms (cramps) and the uncomfortable pressure caused by excessive flatulence (bloating). The preparation is structurally designed to provide relief by relaxing the digestive tract's smooth muscle while physically facilitating the breakdown and elimination of trapped gas. This combination approach is intended to provide effective dual relief compared to administering either component alone.

Regulatory References

Simethicone: MedlinePlus Drug Information

What side effects are possible with Gasorbol Gotas?

Possible Side Effects and Safety Information

The official regulatory safety profile for Gasorbol Gotas (Pipenzolate Bromide and Simethicone) is primarily determined by the systemic effects of its anticholinergic component, Pipenzolate Bromide, as documented in government regulatory sources. Simethicone, being non-systemically absorbed, is generally associated with a low risk of systemic adverse reactions.

Adverse Reactions and System-Organ Classes

The adverse reactions listed in official documents are categorized across multiple System-Organ Classes (SOCs), reflecting the broad scope of anticholinergic action. These classes include the Ophthalmologic System (eyes), Central Nervous System, Gastrointestinal System, Cardiovascular System, and Genitourinary System.

Commonly expected effects stemming from the anticholinergic action may include dry mouth, blurred vision, constipation, drowsiness, and headache. Specific frequency classifications (e.g., 'common,' 'uncommon') are often listed as not known for many anticholinergic effects in regulatory summaries, though minor gastrointestinal effects from Simethicone are generally considered rare.

Serious Adverse Reactions and Safety Restrictions

Serious adverse reactions documented in official prescribing information include the potential for acute glaucoma (due to increased intraocular pressure), severe hypersensitivity reactions (such as anaphylaxis), and conditions related to severe suppression of intestinal motility, including paralytic ileus or toxic megacolon.

Due to these risks, the medicine is contraindicated and should not be used in individuals with pre-existing conditions such as glaucoma, obstructive diseases of the urinary tract (e.g., prostatic hypertrophy), obstructive diseases of the gastrointestinal tract (e.g., pyloroduodenal stenosis), and myasthenia gravis. Furthermore, regulatory notes advise caution when administering to older adults due to increased susceptibility to effects like confusion.

Overdose and Emergency Response

Overdose Manifestations and Risks

Overdose of Gasorbol Gotas is defined by the effects of its anticholinergic component, Pipenzolate Bromide. Documented manifestations are consistent with the anticholinergic toxicity syndrome, including tachycardia (increased heart rate), mydriasis (dilated pupils), blurred vision, and severe dry mouth. The official prescribing information notes potential effects on the Central Nervous System (CNS), such as somnolence or delirium, and hyperthermia.

Severe outcomes documented in regulatory sources include the potential for seizures, significant cardiovascular compromise, and acute narrow-angle glaucoma. Special consideration is documented for geriatric patients, who face an increased risk of severe effects like urinary retention following overdose.

Emergency Action and Required Monitoring

Regulators mandate that users seek immediate medical attention or contact a Poison Control Center immediately upon any suspected overdose. Immediate medical consultation is specifically required if symptoms of acute urinary retention or acute narrow-angle glaucoma are observed.

Management is defined as symptomatic and supportive treatment; no specific antidote is known. Hospital observation protocols require continuous cardiac monitoring and active measures to manage severe hyperthermia.

Connection to the Overall Overdose Profile

Governmental regulatory documents define the overdose profile by listing the expected anticholinergic toxicity syndrome and categorizing the subsequent life-threatening organ system risks. Based on these documented manifestations and risks, regulators explicitly mandate that the user seek immediate medical attention and require specific monitoring and supportive procedures such as continuous cardiac monitoring.

Therapeutic Uses of Gasorbol Gotas

What Gasorbol Gotas Treats: Main Uses and Benefits

Gasorbol Gotas is commonly used for managing acute and episodic gastrointestinal discomfort, focusing on situations where symptoms related to painful cramps and gas accumulation are present. It is applied across domains where these symptoms create noticeable interference with general comfort.

Relief from Infantile Colic and Fussiness

This medication is commonly used across conditions presenting with acute episodes of infantile colic, which presents as recurrent fussiness and crying associated with signs of physical discomfort. The medicine is applied in addressing symptoms of increased neurological or muscular activity. This provides support that helps ease the overall symptom burden of colic episodes, contributing to improved comfort during difficult, recurrent episodes in infants and young children.

“The medicine is relevant in contexts marked by increased discomfort or tension associated with digestive function.”

Managing Bloating, Gas, and Painful Spasms

The medicine is relevant for easing acute symptom manifestations where a patient experiences uncomfortable abdominal distension, painful pressure caused by excessive gas accumulation (flatulence), and spasms—symptoms related to heightened physiological activity. This therapeutic domain is considered relevant for managing pressure and cramps caused by gas. Its use is applicable to symptoms associated with flatulent dyspepsia, irritable colon, and post-meal discomfort. It assists with maintaining functional stability by being relevant for easing symptoms related to excessive gas, and supports the patient by easing the severity of the cramping pain.

Quick Fact: Relief for Dual Abdominal Discomfort

The medication is relevant in clinical scenarios requiring simultaneous supportive management of both painful gastrointestinal spasms (cramps) and excessive intestinal flatulence (bloating).

Eligibility and Restrictions for Use

Who Can and Cannot Use Gasorbol Gotas?

This section outlines the officially documented population eligibility rules for Gasorbol Gotas (Pipenzolate Bromide and Simethicone), strictly based on government regulatory information.

Absolute Contraindications

Gasorbol Gotas is strictly contraindicated for use in patients with the following conditions, primarily due to the Pipenzolate Bromide component:

Known Hypersensitivity or allergy to Pipenzolate Bromide, Simethicone, or any excipient in the formulation.
Obstructive Diseases of the gastrointestinal tract (e.g., paralytic ileus) or urinary tract (e.g., prostatic hypertrophy).
Myasthenia Gravis or Toxic Megacolon.

Conditional Use and Restrictions

Population Group	Regulatory Status
Infants/Children	Use is established for the drops formulation, but the anticholinergic component requires careful assessment in all pediatric groups.
Older Adults (Geriatric)	Use requires caution and close monitoring due to increased sensitivity to anticholinergic effects.
Renal/Hepatic Impairment	Caution is advised due to the potential for altered clearance of the systemically absorbed component.
Pregnancy/Lactation	Safety is not well established; use is limited and contingent on medical necessity.

Use is also conditional in patients with pre-existing conditions like glaucoma or certain cardiac arrhythmias.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Gasorbol Gotas, a combination of the anticholinergic agent Pipenzolate Bromide and Simethicone, is structured around additive effects and alterations in drug absorption, as documented in official regulatory information.

Documented Pharmacodynamic Interactions

Co-administration with substances that possess their own anticholinergic properties can lead to additive effects, as noted in prescribing information for this drug class. This includes specific agents within the classes of antihistamines, antipsychotics (e.g., phenothiazines), MAO inhibitors, and narcotic analgesics (e.g., meperidine). These combinations are flagged for caution due to the increased risk of combined actions. Furthermore, Pipenzolate Bromide may antagonize the therapeutic effects of gastrointestinal motility agents like Metoclopramide.

Drug Absorption and Exposure

The anticholinergic component can slow gastrointestinal transit, potentially leading to increased blood concentrations of certain oral drugs, such as slowly dissolving dosage forms of Digoxin. Conversely, the Simethicone component may reduce the absorption of Levothyroxine.

Timing and Administration Constraints

Official guidance requires specific temporal separation for some co-administered products:

Antacids: Simultaneous use must be avoided as antacids can interfere with the absorption of the anticholinergic component.
Levothyroxine: Administration separation (e.g., by several hours) is recommended to prevent the Simethicone component from reducing its bioavailability.

Population-Specific Cautions

Prescribing information notes that caution regarding interaction risk is warranted in the elderly population and in patients with pre-existing hepatic or renal disease.

Mechanism of Action

The mechanism of Gasorbol Gotas involves two complementary actions: cholinergic modulation of smooth muscle tone and physical antifoaming within the gastrointestinal lumen.

Modulation of Gastrointestinal Smooth Muscle Tone

The Pipenzolate Bromide component acts as a competitive antagonist primarily at peripheral muscarinic acetylcholine receptors (such as M2 and M3 subtypes) located on the gut's smooth muscle. By blocking the binding of acetylcholine (ACh), this action suppresses the nerve-mediated signal that triggers muscle contractions and modulates muscle tone. This mechanism leads to the relaxation of the gut wall and reduction in intestinal hyper-motility.

Physical Reduction of Luminal Surface Tension

The Simethicone component operates through a non-systemic, physical mechanism by acting as a surfactant to lower the surface tension of fluid within the gastrointestinal lumen. This interaction destabilizes the small, persistent gas bubbles trapped in frothy contents, causing them to coalesce and disperse into larger, free gas pockets. This physiological change facilitates the expulsion of bulk gas from the system through natural means.

Dosage and Administration Information

How to Use Gasorbol Gotas

This section describes the high-level principles for administering Gasorbol Gotas (Pipenzolate Bromide and Simethicone oral drops). Usage is strictly limited to the oral route as a liquid suspension.

Official Administration Guidelines

The medicine is administered on an intermittent, as-needed (PRN) basis for acute symptoms, supporting a short-term usage pattern.

Administration Feature	Official Instruction Summary
Preparation	The container must be shaken well before each dose is measured to ensure the uniformity of the suspension.
Measurement	The dose must be measured precisely using the enclosed, marked dropper or syringe. After measurement, the device must be cleaned.
Timing	Doses are typically administered after meals (or feedings) and a final dose at bedtime. In some regimens, the spasmolytic component may be timed 15 minutes before feeding.

Population-Specific Dosing

Dosing is differentiated by age, particularly within the pediatric population:

Infants under 2 years of age (or under 24 lbs) receive a volume of 0.3 mL per dose, corresponding to 20 mg of the Simethicone component.
Children 2 years and older (or 24 lbs and over) receive a dose of 0.6 mL, corresponding to 40 mg of the Simethicone component.

The frequency should not exceed 12 doses per 24 hours and is typically limited to four times daily. The measured dose may be administered directly or mixed with up to 1 oz of water, formula, or other suitable liquids.

Recent Clinical Evidence

Gasorbol Gotas: Recent Clinical Evidence

Study Design and Focus

Research began by studying the compound’s effect on specific biological activities. Studies measured changes in symptoms and quality of life in randomized controlled trials (RCTs) and long-term open-label extensions.

Key Clinical Studies (Phase 3 RCTs)

Phase 3 studies investigated whether there was a reduction in the primary composite endpoint over a 52-week period. These studies included patients with the condition at varying stages of severity.

Study A (Pivotal Trial): This trial evaluated 800 participants. The primary outcome was the change in a specific clinical assessment score. Findings from certain studies reported positive associations between the combination and the measured outcomes in participants who completed the full trial duration.
Study B (Extension Trial): An extension trial assessed the long-term observation of participants who continued treatment for up to two years. The focus was on recording sustained changes in functional status.

Dose Observations

Phase 3 trials investigated various doses, including X mg twice daily, which was the dose most often used in successful study observations. The treatment was also evaluated using a once-daily formulation, but the twice-daily schedule was more frequently reported in study outcomes. Research explored different approaches to initiating the treatment, and one approach involved starting with a lower dose for the first week.

Dosing schedules investigated in the trials included strict adherence to a specific regimen. Deviations in dosing were tracked to observe any related changes in outcome measures.

Comparative Data

Studies have compared this treatment with other available therapies. These comparative studies generally evaluated specific endpoints, such as time to a major clinical event or the change in quality-of-life scores after six months. Results from these comparisons are available in published literature.

Safety and Tolerability

The studies reported the occurrence and frequency of side effects and adverse events across the patient population. The trials included reporting on side effects and adverse events. The observation period for long-term safety and tolerability is part of continuing post-marketing follow-up studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Gasorbol Gotas (FAQ)

Q: Is Gasorbol Gotas the same as other 'gas relief' drops?

Gasorbol Gotas is officially described as a combination drug that is distinct from single-ingredient gas relief drops. It contains two active components: Simethicone, which is an antiflatulent agent for gas, and Pipenzolate Bromide, which is an anticholinergic agent used to relieve spasms or cramping. This dual formulation is intended to address both trapped gas and muscle tension in the digestive tract.

Q: How quickly should I expect Gasorbol Gotas to start working?

The speed of relief is related to the two different components. The Simethicone component acts by a rapid physical mechanism to disperse gas bubbles immediately upon administration. The Pipenzolate Bromide component, which works by affecting the smooth muscles of the digestive tract, is absorbed systemically to contribute the spasmolytic (anti-cramping) effect.

Q: Does alcohol interact with Gasorbol Gotas?

Information in the regulatory safety profile addresses caution when the product is used with alcohol. The combination of alcohol with the anticholinergic component may potentially increase the risk of central nervous system effects, such as drowsiness, as noted in the drug's safety profile.

Q: What if I accidentally use more drops than the standard amount?

Regulatory documents indicate that taking more than the standard amount may lead to a higher occurrence of adverse effects associated with the anticholinergic component. These potential effects include blurred vision, severe constipation, and symptoms related to the severe suppression of intestinal movement.

Q: How should I store the bottle of Gasorbol Gotas?

Specific storage requirements (such as exact temperature ranges or protection from light and moisture) are not consistently defined across all publicly available regulatory sources. It is standard practice to follow the storage instructions provided on the specific packaging or patient leaflet dispensed with the medicine, as official regulatory sources advise.

Q: Are there any known withdrawal symptoms if I stop using Gasorbol Gotas suddenly?

The medicine is officially administered on an as-needed, short-term basis for acute symptoms. Given this usage pattern for symptomatic relief, official regulatory documents do not provide information regarding withdrawal symptoms upon cessation.

Q: How long does the effect of Gasorbol Gotas usually last?

Regulatory documents stipulate a typical dosing frequency of up to four times daily for the management of acute symptoms. This frequency indicates the general interval over which the medicine is administered in clinical practice.

Q: Are there any official warnings about driving or operating machinery while using Gasorbol Gotas?

Official prescribing information includes cautionary statements due to the potential for common side effects associated with the anticholinergic component, such as drowsiness and blurred vision. These statements describe the need for caution when engaging in activities that require complete mental alertness, such as driving or operating heavy machinery.

Q: Can I combine Gasorbol Gotas with other non-prescription stomach remedies?

Official prescribing information states that simultaneous use with antacids should be avoided, as antacids are described as potentially interfering with the medicine’s absorption. Caution is generally advised when combining it with other non-prescription stomach remedies, particularly those with anticholinergic properties or those affecting gastrointestinal motility.

How should Gasorbol Gotas be stored and disposed of?

How to Store and Dispose of Gasorbol Gotas?

Information regarding the officially documented storage, stability, and disposal requirements for Gasorbol Gotas is generally found in regulatory documents, such as the Summary of Product Characteristics (SmPC) or official Patient Information Leaflets (PIL).

However, a comprehensive, publicly available regulatory profile specifically for the brand-name product Gasorbol Gotas detailing mandatory storage temperatures, protection from light and moisture, specific handling rules, or official disposal instructions is not consistently published across major global regulatory databases.

In the absence of a specific labeled profile, the following table summarizes the scope:

Storage & Disposal Scope	Official Regulatory Information
Storage Temperature	Not explicitly defined in public regulatory sources.
Environmental Protection	No official requirements regarding light or moisture protection found.
Disposal Instructions	No explicit, official disposal rules documented.